Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026)
Cytosorbents (CTSO) Capital Expenditures Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Cytosorbents | 25.72 Mn | 20.92 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.93% |
| Dec 31, 2025 | -7.79% |
| Sep 30, 2025 | -40.60% |
| Jun 30, 2025 | -14.50% |
| Mar 31, 2025 | -61.47% |
| Dec 31, 2024 | -13.29% |
| Sep 30, 2024 | 3.76% |
| Jun 30, 2024 | -33.66% |
| Mar 31, 2024 | -31.17% |
| Dec 31, 2023 | -11.55% |
| Sep 30, 2023 | 39.45% |
| Jun 30, 2023 | 5.89% |
| Dec 31, 2022 | 69.85% |
| Sep 30, 2022 | -74.41% |
| Jun 30, 2022 | 81.20% |
| Mar 31, 2022 | 97.55% |
| Dec 31, 2021 | 200.54% |
| Sep 30, 2021 | -87.57% |
| Jun 30, 2021 | 66.02% |
| Mar 31, 2021 | 64.29% |